- Home
- VRAX vs GSIW Comparison
VRAX vs GSIW Comparison
Compare VRAX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- GSIW
- Stock Information
- Founded
- VRAX 2013
- GSIW 2016
- Country
- VRAX United Kingdom
- GSIW Hong Kong
- Employees
- VRAX N/A
- GSIW N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GSIW
- Sector
- VRAX Health Care
- GSIW
- Exchange
- VRAX Nasdaq
- GSIW Nasdaq
- Market Cap
- VRAX 9.1M
- GSIW 8.6M
- IPO Year
- VRAX 2022
- GSIW 2023
- Fundamental
- Price
- VRAX $2.14
- GSIW $0.61
- Analyst Decision
- VRAX
- GSIW
- Analyst Count
- VRAX 0
- GSIW 0
- Target Price
- VRAX N/A
- GSIW N/A
- AVG Volume (30 Days)
- VRAX 487.9K
- GSIW 182.3K
- Earning Date
- VRAX 02-05-2025
- GSIW 12-31-2024
- Dividend Yield
- VRAX N/A
- GSIW N/A
- EPS Growth
- VRAX N/A
- GSIW N/A
- EPS
- VRAX N/A
- GSIW N/A
- Revenue
- VRAX $84,872.00
- GSIW $1,408,469.00
- Revenue This Year
- VRAX $5,169.18
- GSIW N/A
- Revenue Next Year
- VRAX $66.97
- GSIW N/A
- P/E Ratio
- VRAX N/A
- GSIW N/A
- Revenue Growth
- VRAX 7.03
- GSIW N/A
- 52 Week Low
- VRAX $0.60
- GSIW $0.52
- 52 Week High
- VRAX $9.00
- GSIW $15.99
- Technical
- Relative Strength Index (RSI)
- VRAX 49.68
- GSIW 44.96
- Support Level
- VRAX $2.03
- GSIW $0.56
- Resistance Level
- VRAX $2.33
- GSIW $0.69
- Average True Range (ATR)
- VRAX 0.39
- GSIW 0.06
- MACD
- VRAX -0.04
- GSIW 0.01
- Stochastic Oscillator
- VRAX 21.48
- GSIW 35.71
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.